Ferraris R, Bonelli L, Conio M, Fracchia M, Lapertosa G, Aste H
Divisione di Gastroenterologia ed Endoscopia Digestiva, Ospedale Mauriziano Umberto I, Turin, Italy.
Eur J Gastroenterol Hepatol. 1997 Sep;9(9):881-5. doi: 10.1097/00042737-199709000-00011.
Barrett's oesophagus is a premalignant condition leading to adenocarcinoma. The incidence of adenocarcinoma of the oesophagus and the gastrooesophageal junction is rapidly increasing in the USA, northern and central Europe. Data from southern Europe are still unavailable.
To evaluate the incidence of oesophageal adenocarcinoma in a large cohort of Italian patients with Barrett's oesophagus.
A total of 344 patients (253 males and 91 females, age range 19-75 years) with histologically proven Barrett's oesophagus (length of metaplasia > or = 3 cm) were enrolled from November 1987 to June 1995. Endoscopic and histological examinations were scheduled at yearly intervals.
One hundred and eighty-seven patients complied with the follow-up. The mean duration of the follow-up period was 36 months (total follow-up 562 patient-years; range 12-90 months). Low grade dysplasia was found in five patients at the initial examination. During the surveillance period, dysplasia increased in frequency as well as in severity and was found exclusively in the intestinal type of Barrett's oesophagus. In all, dysplastic changes were found in seven patients (five low grade and two high grade) and adenocarcinoma developed in three patients during the follow-up. In a single case, both adenocarcinoma and specialized columnar epithelium developed without any evidence of dysplasia or intestinal metaplasia at the previous follow-up examination. This prospective study shows an incidence of adenocarcinoma in Barrett's oesophagus of 1/187 patient-years. When only patients with specialized columnar epithelium were considered, the risk of adenocarcinoma was 1/88 patient-years.
The present report shows that the incidence of adenocarcinoma in Italian Barrett's oesophagus patients is in the range of that reported from other Western countries.
巴雷特食管是一种可发展为腺癌的癌前病变。在美国、北欧和中欧,食管及胃食管交界处腺癌的发病率正在迅速上升。来自南欧的数据仍然缺乏。
评估一大群意大利巴雷特食管患者中食管腺癌的发病率。
1987年11月至1995年6月,共纳入344例经组织学证实的巴雷特食管患者(男性253例,女性91例,年龄范围19 - 75岁),化生长度≥3 cm。每年安排内镜和组织学检查。
187例患者完成了随访。随访期的平均时长为36个月(总随访时长562患者年;范围12 - 90个月)。初次检查时,5例患者发现低级别异型增生。在监测期内,异型增生的频率和严重程度均增加,且仅在肠化生型巴雷特食管中发现。随访期间,共有7例患者出现异型增生性改变(5例低级别,2例高级别),3例患者发生腺癌。在1例患者中,腺癌和特殊柱状上皮在之前的随访检查中均无异型增生或肠化生证据的情况下发生。这项前瞻性研究显示,巴雷特食管腺癌的发病率为1/187患者年。仅考虑特殊柱状上皮患者时,腺癌风险为1/88患者年。
本报告显示,意大利巴雷特食管患者中腺癌的发病率与其他西方国家报告的发病率范围相当。